<DOC>
	<DOCNO>NCT02586857</DOCNO>
	<brief_summary>A Phase 1b/2 , multicenter , open-label study design evaluate efficacy safety ACP-196 subject recurrent GBM progress 1 2 prior systemic treatment regimen .</brief_summary>
	<brief_title>A Phase 1b/2 , Multicenter , Open-label Study ACP-196 Subjects With Recurrent Glioblastoma Multiforme ( GBM )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Histologically confirm GBM first second recurrence concurrent adjuvant chemotherapy radiotherapy ( must receive temozolomide ) . Radiographic demonstration disease progression MRI follow prior therapy . ECOG performance status ≤ 2 . Life expectancy ≥ 12 week . Completion prior anticancer therapy first ACP196 dose . Three prior line systemic therapy GBM . Significant cardiovascular disease . Evidence bleed diathesis coagulopathy . Requires urgent palliative intervention primary disease . History stroke clinically significant intracranial hemorrhage within 6 month first dose study drug . Breastfeeding pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>GBM</keyword>
</DOC>